 |
|
Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma
Changgon Kim, Sang Eun Yoon, Hyun-Young Kim, Duck Cho, Junhun Cho, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2026;41(2):296-306. Published online 2026 Mar 1 DOI: https://doi.org/10.3904/kjim.2025.282
|
|
Citations to this article as recorded by
 A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma
Ho-Young Yhim
The Korean Journal of Internal Medicine.2026; 41(2): 183. CrossRef Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis
Jan Christian Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel, Fizza Imran, Lucas Mix, Andreas Riedel, Robin Sanderson, Urban Novak, Ron Ram, Maria-Luisa Schubert, Maxime Delforge, David Beauvais, Daniela Taurino, Robin Noel, Lucia Lopez Corr
Bone Marrow Transplantation.2026;[Epub] CrossRef
|